Washington, Sept. 26 (U.S.) “It’s a matter of days, not weeks” before the company and German partner BioNTech provide data to US regulators for a federal authorization of a COVID-19 vaccine for children ages 5 to 11, the CEO of Pfizer said. .
This would be an important step toward starting vaccinations for these young people, especially with children now back in school, which has led to a major surge in children’s infections, according to the Associated Press.
Pfizer said last week that its vaccine works for that age group and that it has tested a much lower dose than the vaccine already available to anyone 12 and older.
The company said that after kids ages 5 to 11 got their second dose during testing, they developed levels of anti-coronavirus antibodies just as strong as teens and young adults who get the regular strength shots.
Pfizer CEO Albert Burla said Sunday that if the Food and Drug Administration approves the company’s request, “we will be prepared in our manufacturing to provide this new vaccine formulation.”
And when it comes to the coronavirus pandemic, he told ABC “This Week” that in a year’s time, “I think we’ll be able to get back to normal life. I don’t think that means that the variables won’t keep coming up. And I don’t think that means we should.” Being able to live our lives…without vaccinations, basically.”
Burla also said that “we will have vaccines … that will last for at least a year” and that “the most likely scenario is annual revaccination.”